Down regulation of Hematopoietic SH2 domain containing (HSH2D) in the progression of the chronic myelogenous leukemia (2006)
- Authors:
- USP affiliated authors: MOREIRA FILHO, CARLOS ALBERTO - ICB ; CASTRO, FABÍOLA ATTIÉ DE - FCFRP ; MENDES, JOAO GUSTAVO PESSINI AMARANTE - ICB
- Unidades: ICB; FCFRP
- Assunto: IMUNOLOGIA
- Language: Inglês
- Abstract: Introduction and aims: Chronic Myelogenous Leukemia (CML) is a mieloproliferative hematopoietic stem cell disease, in which more than 90% of patients present Bcr-Abl fusion protein. This oncoprotein is responsible for apoptosis resistance and malignant transformation in these cells. In a previous study, our group has shown that ectopic expression of Bcr-Abl in cell lines promotes a differential expression in several genes. One important down regulated gene is hematopoietic SH2 domain containing (hsh2d). It encodes a protein described as acting downstream of CD28 to regulate IL-2 promoter, during T cell activation. However, it is not clear its contribution in others signaling pathways. In the light of these observations we investigated the expression of the hsh2d mRNA in Bcr-Abl transfected cell lines previously established in our lab, as well as in cells from CML patients. Methods: We studied 10 health controls and 42 CML patients in different phases (11 chronic phase, 10 accelerated phase, 11 blastic phase, and 9 cytogenetic remission post-Gleevec®). Peripheral blood mononuclear cells were isolated to cDNA synthesis and expression of the hsh2d was analyzed by SybrGreen Real Time RT-PCR.Results: The down regulation of hsh2d was confirmed in HL-60.Bcr-Abl, HeLa.Bcr-Abl and SKW.Bcr-Abl when these cells were compared to the wild type lineages. This profile of expression was maintained in HeLa.Bcr-Abl/KR -Bcr-Abl kinase-deficient expressing cell - suggesting that hsh2d down regulation is independent of Bcr-Abl kinase activity. In addition, we observed a positive correlation between the CML phases and the decreased hsh2d expression. Interestingly, hsh2d begin to recover normal levels in cytogenetic remission patients. Conclusions: Taken together, our results show that Bcr-Abl down-regulates the expression of hsh2d, an envent that may contribute to the development of Ph-Chromosome-positive leukemia. In addition, hsh2d may be used as a molecule for determining the progression of the disease
- Imprenta:
- Source:
- Título: Abstracts
- Conference titles: Meeting of the Brazilian Society for Immunology
-
ABNT
PEREIRA, W O et al. Down regulation of Hematopoietic SH2 domain containing (HSH2D) in the progression of the chronic myelogenous leukemia. 2006, Anais.. São Paulo: Instituto de Ciências Biomédicas, Universidade de São Paulo, 2006. . Acesso em: 28 jan. 2026. -
APA
Pereira, W. O., Carvalho, D. D., Leroy, J. M. G., Bueno-da-Silva, A. E., Jacysyn, J. F., Tobo, P. R., et al. (2006). Down regulation of Hematopoietic SH2 domain containing (HSH2D) in the progression of the chronic myelogenous leukemia. In Abstracts. São Paulo: Instituto de Ciências Biomédicas, Universidade de São Paulo. -
NLM
Pereira WO, Carvalho DD, Leroy JMG, Bueno-da-Silva AE, Jacysyn JF, Tobo PR, Zanichelli MA, Camanho D, Collassanti MD, Lopes LR, Hamerschlak N, Okamoto OK, Moreira-Filho CA, Castro FA de, Amarante-Mendes JGP. Down regulation of Hematopoietic SH2 domain containing (HSH2D) in the progression of the chronic myelogenous leukemia. Abstracts. 2006 ;[citado 2026 jan. 28 ] -
Vancouver
Pereira WO, Carvalho DD, Leroy JMG, Bueno-da-Silva AE, Jacysyn JF, Tobo PR, Zanichelli MA, Camanho D, Collassanti MD, Lopes LR, Hamerschlak N, Okamoto OK, Moreira-Filho CA, Castro FA de, Amarante-Mendes JGP. Down regulation of Hematopoietic SH2 domain containing (HSH2D) in the progression of the chronic myelogenous leukemia. Abstracts. 2006 ;[citado 2026 jan. 28 ] - Indoleamine 2,3-dioxygenase expression in chronic myelogenous leukemia patients: association with disease progression
- Expression of pro-apoptotic bid and bik genes is decreased in chronic myeloid leukemia and low levels of bik MRNA are associated with lack of response to imatinib treatment
- Genomic approach to understand the mechanisms invilved in Bcr-Abl-mediated resistance to apoptosis
- Correlation between metabolic alterations and apoptosis resistance confered by BCR-ABL expression
- Survivin and CIAP-1 gene expression is linked to chronic myeloid leukemia progression and poor response to imatinib
- Survivin and CIAP-1 gene expression is linked to chronic myeloid leukemia progression and poor response to imatinib
- Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide
- Study of pro and anti-apoptotic genes to understand the resistance of apoptosis mediated by Bcr-Abl
- Development and characterization of murine models of T lymphoma to investigate the impact of oncogene expression
- Cosmomycin D, an anthracycline more potent than Doxorubicin for induction of tumor cell death, synergize with imatinib mesilate to induce apoptosis in Bcr-Abl-positive cells
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
